The prognostic role of loss of insulin-like growth factor-binding protein-3 expression in head and neck carcinogenesis

Cancer Letters

Volumn 239, Issue 1, 2006, Pages 136-143

  Papadimitrakopoulou, Vassiliki A ^a   Brown, Erika N ^a   Liu, Diane D ^a   El Naggar, Adel K ^a   Jack Lee, J ^a   Hong, Waun Ki ^a   Lee, Ho Young ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Head and neck cancer; Insulin like growth factor binding protein 3

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX INJURY; MALE; MOUTH LESION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS; TONGUE CARCINOMA;

AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DOWN-REGULATION; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TONGUE NEOPLASMS;

EID: 33745355181     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.08.009     Document Type: Article

References (36)

1. Forastiere A., Koch W., Trotti A., and Sidransky D. Head and neck cancer. N. Engl. J. Med. 345 (2001) 1890-1900
2. Vogelstein B., and Kinzler K.W. The multistep nature of cancer. Trends Genet. 9 (1993) 138-141
3. Brennan J.A., Mao L., Hruban R.H., Boyle J.O., Eby Y.J., Koch W.M., et al. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 332 (1995) 429-435
4. Partridge M., Emilion G., and Langdon J.D. Loh at 3p correlates with a poor survival in oral squamous cell carcinoma. Br. J. Cancer 73 (1996) 366-371
5. Mao L., Lee J.S., Fan Y.H., Ro J.Y., Batsakis J.G., Lippman S., et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat. Med. 2 (1996) 682-685
6. Grandis J.R., Tweardy D.J., and Melhem M.F. Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. Clin. Cancer Res. 4 (1998) 13-20
7. Grandis J.R., Melhem M.F., Gooding W.E., Day R., Holst V.A., Wagener M.M., et al. Levels of tgf-alpha and egfr protein in head and neck squamous cell carcinoma and patient survival. J. Natl Cancer Inst. 90 (1998) 824-832
8. Yu H., Spitz M.R., Mistry J., Gu J., Hong W.K., and Wu X. Plasma levels of insulin-like growth factor-i and lung cancer risk: A case-control analysis. J. Natl Cancer Inst. 91 (1999) 151-156
9. Jones J.I., and Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 16 (1995) 3-34
10. Dunn S.E., Hardman R.A., Kari F.W., and Barrett J.C. Insulin-like growth factor 1 (igf-1) alters drug sensitivity of hbl100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res. 57 (1997) 2687-2693
11. Prager D., Li H.L., Asa S., and Melmed S. Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor i receptor mutant. Proc. Natl Acad. Sci. USA 91 (1994) 2181-2185
12. LeRoith D., Werner H., Beitner-Johnson D., and Roberts Jr. C.T. Molecular and cellular aspects of the insulin-like growth factor i receptor. Endocr. Rev. 16 (1995) 143-163
13. Stewart C.E., and Rotwein P. Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. Physiol. Rev. 76 (1996) 1005-1026
14. Baxter R.C. Signalling pathways involved in antiproliferative effects of igfbp-3: a review. Mol. Pathol. 54 (2001) 145-148
15. Wu X., Zhao H., Do K.A., Johnson M.M., Dong Q., Hong W.K., and Spitz M.R. Serum levels of insulin growth factor (igf-i) and igf-binding protein predict risk of second primary tumors in patients with head and neck cancer. Clin. Cancer Res. 10 (2004) 3988-3995
16. Lee H.Y., Chun K.H., Liu B., Wiehle S.A., Cristiano R.J., Hong W.K., et al. Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer. Cancer Res. 62 (2002) 3530-3537
17. Rajah R., Valentinis B., and Cohen P. Insulin-like growth factor (igf)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and igf-independent mechanism. J. Biol. Chem. 272 (1997) 12181-12188
18. Deal C., Ma J., Wilkin F., Paquette J., Rozen F., Ge B., et al. Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J. Clin. Endocrinol. Metab. 86 (2001) 1274-1280
19. Hanafusa T., Yumoto Y., Nouso K., Nakatsukasa H., Onishi T., Fujikawa T., et al. Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Lett. 176 (2002) 149-158
20. Oh Y., Muller H.L., Ng L., and Rosenfeld R.G. Transforming growth factor-beta-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action. J. Biol. Chem. 270 (1995) 13589-13592
21. Yu H., and Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J. Natl Cancer Inst. 92 (2000) 1472-1489
22. Grimberg A., and Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J. Cell. Physiol. 183 (2000) 1-9
23. Buckbinder L., Talbott R., Velasco-Miguel S., Takenaka I., Faha B., Seizinger B.R., and Kley N. Induction of the growth inhibitor igf-binding protein 3 by p53. Nature 377 (1995) 646-649
24. Conover C.A., and De Leon D.D. Acid-activated insulin-like growth factor-binding protein-3 proteolysis in normal and transformed cells. Role of cathepsin d. J. Biol. Chem. 269 (1994) 7076-7080
25. Chang Y.S., Kong G., Sun S., Liu D., El-Naggar A.K., Khuri F.R., et al. Clinical significance of insulin-like growth factor-binding protein-3 expression in stage i non-small cell lung cancer. Clin. Cancer Res. 8 (2002) 3796-3802
26. Chang Y.S., Wang L., Liu D., Mao L., Hong W.K., Khuri F.R., and Lee H.Y. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage i non-small cell lung cancer. Clin. Cancer Res. 8 (2002) 3669-3675
27. Del Giudice M.E., Fantus I.G., Ezzat S., McKeown-Eyssen G., Page D., and Goodwin P.J. Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res. Treat. 47 (1998) 111-120
28. Wolk A., Mantzoros C.S., Andersson S.O., Bergstrom R., Signorello L.B., Lagiou P., et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J. Natl Cancer Inst. 90 (1998) 911-915
29. Firth S.M., Fanayan S., Benn D., and Baxter R.C. Development of resistance to insulin-like growth factor binding protein-3 in transfected t47d breast cancer cells. Biochem. Biophys. Res. Commun. 246 (1998) 325-329
30. Collett-Solberg P.F., and Cohen P. The role of the insulin-like growth factor binding proteins and the igfbp proteases in modulating igf action. Endocrinol. Metab. Clin. North Am. 25 (1996) 591-614
31. McCusker R.H., Busby W.H., Dehoff M.H., Camacho-Hubner C., and Clemmons D.R. Insulin-like growth factor (igf) binding to cell monolayers is directly modulated by the addition of igf-binding proteins. Endocrinology 129 (1991) 939-949
32. Claussen M., Kubler B., Wendland M., Neifer K., Schmidt B., Zapf J., and Braulke T. Proteolysis of insulin-like growth factors (igf) and igf binding proteins by cathepsin d. Endocrinology 138 (1997) 3797-3803
33. Fowlkes J.L., Enghild J.J., Suzuki K., and Nagase H. Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. J. Biol. Chem. 269 (1994) 25742-25746
34. Manes S., Llorente M., Lacalle R.A., Gomez-Mouton C., Kremer L., Mira E., and Martinez A.C. The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in du-145 carcinoma cells. J. Biol. Chem. 274 (1999) 6935-6945
35. Marinaro J.A., Hendrich E.C., Leeding K.S., and Bach L.A. Hacat human keratinocytes express igf-ii, igfbp-6, and an acid-activated protease with activity against igfbp-6. Am. J. Physiol. 276 (1999) E536-E542
36. Baserga R. The igf-i receptor in cancer research. Exp. Cell Res. 253 (1999) 1-6